The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape

Doehn C, Bögemann M, Grünwald V, Welslau M, Bedke J, Schostak M, Wolf T, Ehneß R, Degenkolbe E, Witecy S, Goebell P (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Cancers MDPI

Book Volume: 14

Article Number: 5486

Journal Issue: 22

DOI: 10.3390/cancers14225486

Abstract

The approval of tyrosine kinase inhibitors and checkpoint inhibitors represented a remarkable progression in the therapeutic landscape for the treatment of metastatic renal cell carcinoma (mRCC). Yet, in the ever-evolving landscape of mRCC treatment, real-world data on these agents, including pazopanib, are scarce. The non-interventional PAZOREAL study investigated the effectiveness and safety of pazopanib (first-line), nivolumab (second-line), and everolimus (second- and third-line) in a real-life setting. The multicentric study included 376 mRCC patients who received first-line treatment with pazopanib and assessed time on the drug (primary endpoint), overall survival, best responses, disease control rates, as well as safety signals and health-related quality of life. The median overall time on the drug was 10.0 months, with first-line pazopanib having a median time on drug of 6.3 months. The median overall survival was 35.9 months. The disease control rate for first-line pazopanib was 56.9%. No new safety signals were detected. PAZOREAL provides valuable real-world data for first-line treatment with pazopanib.

Authors with CRIS profile

Peter Goebell Urologische Klinik

Involved external institutions

Urologikum Lübeck DE Germany (DE) Universitätsklinikum Münster DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) Klinikum Aschaffenburg DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Universitätsklinikum Magdeburg A.ö.R. DE Germany (DE) Novartis AG CH Switzerland (CH) APOGEPHA Arzneimittel GmbH DE Germany (DE)

How to cite

APA:

Doehn, C., Bögemann, M., Grünwald, V., Welslau, M., Bedke, J., Schostak, M.,... Goebell, P. (2022). The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape. Cancers, 14(22). https://doi.org/10.3390/cancers14225486

MLA:

Doehn, Christian, et al. "The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape." Cancers 14.22 (2022).

BibTeX: Download